Thrombolex, Inc. articles

Medical device start-up companies must focus on innovation, regulatory compliance, efficient processes and prudent financial management in order to survive. Smart MedTech companies prioritize their funding to only support innovation which will result in new products that fulfill significant unmet clinical needs over the long-term. Thrombolex, a relatively new entrant into the MedTech sector, is a proven, serial innovator that understands this prioritization need. Their experienced leadership

February 9, 2021—Findings from the first-in-human (FIH) study assessing the safety and feasibility of the Bashir endovascular catheter (BEC; Thrombolex, Inc.) for the treatment of acute intermediate-risk pulmonary embolism (PE) were published by Akhilesh K. Sista, MD, et al in

PE is the most common preventable cause of death among hospital patients in the United States. VTE is a leading cause of death and disability worldwide and has the third-highest mortality rate out of any cardiovascular disease, behind myocardial infarctions and stroke. Unlike myocardial infractions and stroke, where mortality has improved considerably, VTE has seen an increase in cases, with no demonstrable change in mortality over the past decade. As a result, VTE is widely recognized